Cytokinetics Interest Expense vs Operating Income Analysis

CYTK Stock  USD 49.10  1.43  3.00%   
Cytokinetics financial indicator trend analysis is way more than just evaluating Cytokinetics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cytokinetics is a good investment. Please check the relationship between Cytokinetics Interest Expense and its Operating Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.

Interest Expense vs Operating Income

Interest Expense vs Operating Income Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cytokinetics Interest Expense account and Operating Income. At this time, the significance of the direction appears to have pay attention.
The correlation between Cytokinetics' Interest Expense and Operating Income is -0.91. Overlapping area represents the amount of variation of Interest Expense that can explain the historical movement of Operating Income in the same time period over historical financial statements of Cytokinetics, assuming nothing else is changed. The correlation between historical values of Cytokinetics' Interest Expense and Operating Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Interest Expense of Cytokinetics are associated (or correlated) with its Operating Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Operating Income has no effect on the direction of Interest Expense i.e., Cytokinetics' Interest Expense and Operating Income go up and down completely randomly.

Correlation Coefficient

-0.91
Relationship DirectionNegative 
Relationship StrengthSignificant

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Operating Income

Operating Income is the amount of profit realized from Cytokinetics operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Cytokinetics is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.
Most indicators from Cytokinetics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cytokinetics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.At this time, Cytokinetics' Selling General Administrative is quite stable compared to the past year. Sales General And Administrative To Revenue is expected to rise to 24.21 this year, although Enterprise Value Multiple is projected to rise to (18.10).
 2021 2022 2023 2024 (projected)
Other Operating Expenses256.7M418.8M503.7M528.9M
Interest Expense29.3M51.2M57.7M60.6M

Cytokinetics fundamental ratios Correlations

0.9-0.490.87-0.910.030.920.940.940.940.840.920.960.950.460.980.720.930.370.620.980.170.410.970.930.94
0.9-0.80.99-0.95-0.030.860.990.890.990.850.940.880.930.180.930.580.810.320.810.92-0.080.390.920.850.95
-0.49-0.8-0.820.72-0.06-0.54-0.76-0.56-0.75-0.57-0.68-0.57-0.570.23-0.55-0.3-0.38-0.25-0.89-0.550.4-0.17-0.56-0.51-0.64
0.870.99-0.82-0.920.010.810.970.850.970.80.910.840.910.120.910.490.780.350.790.88-0.10.380.90.820.93
-0.91-0.950.72-0.920.09-0.95-0.96-0.98-0.96-0.84-0.95-0.94-0.89-0.34-0.92-0.7-0.81-0.18-0.84-0.92-0.02-0.46-0.91-0.89-0.92
0.03-0.03-0.060.010.09-0.090.06-0.130.04-0.2-0.130.13-0.05-0.08-0.01-0.130.030.86-0.050.03-0.13-0.290.06-0.1-0.05
0.920.86-0.540.81-0.95-0.090.90.970.90.810.920.940.830.510.90.770.790.150.70.930.120.350.90.890.84
0.940.99-0.760.97-0.960.060.90.921.00.850.940.940.940.240.950.650.850.380.810.95-0.040.370.950.890.95
0.940.89-0.560.85-0.98-0.130.970.920.930.840.930.950.890.470.930.760.850.130.750.940.140.470.910.910.9
0.940.99-0.750.97-0.960.040.91.00.930.860.950.940.940.260.950.660.850.370.810.95-0.030.370.940.90.96
0.840.85-0.570.8-0.84-0.20.810.850.840.860.910.790.820.260.840.810.730.120.710.86-0.060.290.820.730.84
0.920.94-0.680.91-0.95-0.130.920.940.930.950.910.880.940.410.940.750.860.220.810.90.090.280.870.870.96
0.960.88-0.570.84-0.940.130.940.940.950.940.790.880.880.420.920.750.860.380.720.960.090.380.940.920.89
0.950.93-0.570.91-0.89-0.050.830.940.890.940.820.940.880.380.980.630.960.360.680.90.180.40.90.910.99
0.460.180.230.12-0.34-0.080.510.240.470.260.260.410.420.380.40.470.520.030.060.370.65-0.060.330.440.35
0.980.93-0.550.91-0.92-0.010.90.950.930.950.840.940.920.980.40.670.950.360.660.950.130.410.940.920.97
0.720.58-0.30.49-0.7-0.130.770.650.760.660.810.750.750.630.470.670.650.060.590.720.080.190.620.680.64
0.930.81-0.380.78-0.810.030.790.850.850.850.730.860.860.960.520.950.650.410.560.850.340.370.840.880.94
0.370.32-0.250.35-0.180.860.150.380.130.370.120.220.380.360.030.360.060.410.140.34-0.03-0.130.370.240.35
0.620.81-0.890.79-0.84-0.050.70.810.750.810.710.810.720.680.060.660.590.560.140.64-0.150.240.610.650.76
0.980.92-0.550.88-0.920.030.930.950.940.950.860.90.960.90.370.950.720.850.340.640.020.410.990.910.9
0.17-0.080.4-0.1-0.02-0.130.12-0.040.14-0.03-0.060.090.090.180.650.130.080.34-0.03-0.150.02-0.010.010.150.14
0.410.39-0.170.38-0.46-0.290.350.370.470.370.290.280.380.4-0.060.410.190.37-0.130.240.41-0.010.430.440.39
0.970.92-0.560.9-0.910.060.90.950.910.940.820.870.940.90.330.940.620.840.370.610.990.010.430.890.89
0.930.85-0.510.82-0.89-0.10.890.890.910.90.730.870.920.910.440.920.680.880.240.650.910.150.440.890.9
0.940.95-0.640.93-0.92-0.050.840.950.90.960.840.960.890.990.350.970.640.940.350.760.90.140.390.890.9
Click cells to compare fundamentals

Cytokinetics Account Relationship Matchups

Cytokinetics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets289.8M533.8M841.3M1.0B824.3M865.5M
Short Long Term Debt Total136.1M138.9M269.9M749.3M755.8M793.6M
Total Stockholder Equity(10.9M)113.4M243.9M(107.9M)(386.3M)(367.0M)
Net Debt99.6M56.0M157.3M683.8M642.7M674.9M
Retained Earnings(865.0M)(992.3M)(1.2B)(1.6B)(2.1B)(2.0B)
Common Stock Shares Outstanding57.6M64.5M76.9M89.8M96.5M101.4M
Liabilities And Stockholders Equity289.8M533.8M841.3M1.0B824.3M865.5M
Non Current Liabilities Total274.7M389.2M525.6M1.0B1.1B1.2B
Other Stockholder Equity853.3M1.1B1.5B1.5B1.7B1.8B
Total Liab300.8M420.4M597.5M1.1B1.2B1.3B
Other Current Liab1.1M17.6M21.0M33.3M35.3M37.1M
Total Current Liabilities26.0M31.2M71.9M84.6M102.7M107.8M
Other Liab143.3M253.1M270.5M300.5M345.6M362.9M
Property Plant And Equipment Net13.4M22.6M146.4M163.2M147.7M155.1M
Current Deferred Revenue12.1M19.3M34.4M12.4M14.2M12.3M
Accounts Payable8.2M8.1M21.1M25.6M21.5M22.6M
Cash36.4M83.0M112.7M65.6M113.0M118.7M
Non Current Assets Total56.1M59.6M305.6M219.6M196.3M206.1M
Non Currrent Assets Other8.9M9.3M7.2M9.7M8.0M4.0M
Long Term Debt45.1M46.2M47.4M63.8M607.4M637.7M
Cash And Short Term Investments225.1M464.1M471.6M782.6M614.8M645.6M
Net Receivables5.2M4.4M51.8M147K1.3M1.2M
Common Stock Total Equity59K70K84K94K108.1K58.5K
Short Term Investments188.7M381.1M359.0M717.0M501.8M526.9M
Other Current Assets3.5M5.7M12.2M12.5M11.9M12.5M
Property Plant And Equipment Gross13.4M22.6M146.4M163.2M176.1M184.9M
Total Current Assets233.8M474.2M535.7M795.2M628.1M659.5M
Accumulated Other Comprehensive Income343K500K679K(869K)(3.6M)(10.5K)
Short Term Debt4.6M5.6M29.7M25.7M45.9M48.2M
Common Stock59K70K84K94K102K96.9K
Property Plant Equipment4.5M13.3M73.3M80.5M92.5M97.1M
Net Tangible Assets(10.9M)113.4M243.9M(107.9M)(97.1M)(92.3M)
Retained Earnings Total Equity(865.0M)(992.3M)(1.2B)(1.6B)(1.4B)(1.4B)
Capital Surpluse853.3M1.1B1.5B1.5B1.7B921.5M
Long Term Investments42.7M37.0M152.1M46.7M40.5M38.0M
Long Term Debt Total45.1M46.2M47.4M63.8M73.4M43.5M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Cytokinetics is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Cytokinetics Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Cytokinetics Stock. Highlighted below are key reports to facilitate an investment decision about Cytokinetics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.
You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(5.38)
Revenue Per Share
0.03
Quarterly Revenue Growth
0.225
Return On Assets
(0.30)
Return On Equity
(5.72)
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.